Conus peptides: biodiversity-based discovery and exogenomics by Olivera, Baldomero M.
MINIREVIEW This paper is available online a t www.jbc.org
THE JOURNAL OF BIOLOGICAL. CHEMISTRY VOL. 281, NO. 42, pp. 31173-31177, October 20,2006 









C o n u s  P e p t i d e s :  
B i o d i v e r s i t y - b a s e d  D i s c o v e r y  
a n d  E x o g e n o m i c s *
Published. - BC Papers in Press, August 11, 2006. DOi 10.1074/jbc.R600020200
Baldomero M. Olivera1
From the Department of Biology, University of Utah,
Salt Lake City, Utah 84112
The venoms of the —700 species of predatory cone snails 
(genus Conus) are being systematically characterized. Each 
Conus species contains 100-200 small, highly structured 
venom peptides (colloquially known as conotoxins), which are 
synthesized and secreted in a venom duct (for overviews, see 
Refs. 1-3). The biomedical potential of these small venom pep­
tides is now well established; recent developments are summa­
rized below. Additionally, the genetic basis and biological 
rationale for Conus peptide diversity is addressed.
Conus peptide genes belong to a general class whose gene 
products are targeted to other organisms; the extensive molec­
ular analysis carried out on the Conus genes revealed that these 
diversify extremely rapidly. Understanding this class of genes 
may require a specialized framework with features distinct 
from conventional genomics, which we will refer to as “exog­
enomics” (the gene products are targeted exogenously rather 
than endogenously). The interdisciplinary paradigm that has 
evolved for the systematic discovery of Conus venom peptides, 
if applied more broadly, should prove fruitful for generally 
exploring chemical diversity from the animal biodiversity that 
surrounds us.
Therapeutic Applications of Conus Peptides
Six different Conus peptides have reached human clinical 
trials (Table 1); a significant milestone was the approval of a 
Conus peptide as a commercial drug for intractable pain by the 
Food and Administration in December 2004. The commercial 
product, Prialt (generieally called ziconitide) is identical to the 
natural peptide produced by the magician’s cone snail, Conus 
magus, originally designated w-conotoxin M V IIA  (4-7). This is 
one of a class of peptides from fish-hunting cone snail venoms 
exhibiting high specificity for the N-type calcium channel 
(Cav2.2). Another peptide that acts by the same mechanism, 
w-conotoxin GVIA from Conus geographus, is the most widely 
used Conus peptide in neuroscience, with —2000 research 
papers in the literature using this compound as a pharmacolog­
ical tool (3).
A high proportion of the first conopeptides characterized 
have reached clinical development; of the first 30 peptides puri­
fied from Conus venoms, 10% reached at least Phase 1 human
'This minireview will be reprinted in the 2006 Minireview Compendium, 
which will be available in January, 2007. The work of the author's labora­
tory is supported by National Institute of General Medical Sciences Grant 
GM48677.
1 To whom correspondence should be addressed. E-mail: olivera@biology. 
utah.edu.
clinical trials. A significant fraction of these Conus peptides in 
development are potential therapeutics for pain (see Table 1). 
Although pharmaceutical companies have mostly focused on 
opioids for treating severe pain, the analgesic Conus venom 
peptides in development work through five distinct mecha­
nisms, of which none are opioid-based. One peptide, k-PVIIA, a 
I<+ channel blocker has been effective in decreasing cardiac 
damage in animal models of myocardial infarction (8, 9).
The diversity of analgesic conopeptides in Table 1 illustrates 
an important application of Conus peptides: identifying new 
pharmacological mechanisms. The N-type calcium channel 
had not been identified as a drug target for severe pain until 
w-conotoxins were shown to be analgesic. Subsequently, small 
molecule drug candidates targeting N-type calcium channels 
were developed (10, 11 ); some are now undergoing human clin­
ical trials. Thus, even those Conus peptides not directly devel­
oped as therapeutics can be extremely valuable for identifying 
potential molecular targets for novel drugs.
Gene Superfamilies Encoding Conus Peptides Rapidly 
Diversify
Conus venom peptides are being rapidly identified by using 
molecular cloning to deduce amino acid sequences. The con­
tinuously expanding data base provides an ever stronger case 
for extremely rapid diversification of genes encoding Conus 
peptides; each species has its own repertoire of 100-200 differ­
ent venom peptides, distinct from that of any other species. 
Thus, living Conus are likely to express >70,000 different pep­
tides in their venoms (3).
Most of this peptide diversity is generated by the greatly 
accelerated evolution of a few gene superfamilies; the nine 
superfamilies described to date are shown in Table 2; each 
Conus peptide gene encodes a precursor that typically has an 
N-terminal signal sequence of —25 amino acids, an intervening 
“pro” region (—2 0 -4 0  amino acids, depending on the gene 
superfamily), and at the C-terminal end, the mature toxin 
(10 -40  amino acids for most superfamilies) in single copy (4). 
This rather conventional prepropeptide organization masks a 
striking and unconventional evolutionary pattern. Compari­
sons between superfamily genes from different Conus species 
reveal an extraordinary juxtaposition; signal sequences are con­
served to an unprecedented degree but mature toxin regions 
are hypermutated (see Fig. 1). PCR primers designed from the 
conserved sequences make discovery of additional peptides in a 
superfamily using PCR straightforward. The predicted peptides 
can be chemically synthesized; for Conus peptides in the 10-25  
amino acid size range, this is generally straightforward. One 
potential problem is the high frequency of post-translational 
modification in some Conus peptide families. The post-trans­
lational modification of Conus peptides was recently reviewed 
(12); more progress is needed to accurately predict post-trans­
lational modification a priori from cloned sequences.
The mechanisms that underlie conopeptide gene hypermu­
tation have not been elucidated. Although there is strong diver­
sifying selection, the pattern and frequency of sequence




















Conus venom peptides w ith therapeutic potential





N-type calcium channel (Cav2.2) w-MVIIA (Prialt; zicontide) Pain Elan (Neurex) Approved by FDA 12/04 5
co-CVID (AM336) Pain Amrad Phase 1 25
Neurotensin receptor Contulakin-G (CGX-1160) Pain Cognetix Phase 1 26
Norepinephrine transporter ^-MrlA (derivative) (Xen-2174) Pain Xenome Phase 1 27
Nicotinic receptors a-Vcl.l (ACV'l) Pain Metabolic Phase 1 28
NMD A* receptors Conantoldn-G (CGX-1007) Epilepsy; pain Cognetix Phase 1 29
I<+ channels (Kvl subfamily) k-PVIIA (CGX-1051) Myocardial infarction Cognetix Pre-clinical 8
Na+ channels /LiO-MrVIB (CGX-1002) Pain Cognetix Pre-clinical 30
a See supplemental material for sequences and structures.
AT-Methyl-D-aspartate.
TABLE 2
Conus venom peptide gene superfamilies
Superfamily (Ref.) Cys pattern(s) (designated framework no.) Pharmacological family** Target*
A (14) CC-C-C (I/II) a Nicotinic receptors
P a-Adrenergic receptors
A (16) CC-C-C-C-C (IV) aA Nicotinic receptors
kA I<+ channels?
M (15) CC-C-C-CC (III) ix Na+ channels
kM I<+ channels
Nicotinic receptors
0(3) C-C-CC-C-C (VI/VII) <0 Ca2+ channels
K I<+ channels
8 Na+ channels
T (31) CC-----CC (V) None defined Unknown
T (32) CC— c x o c * Catecholamine transporter
S (33, 34) C-C-C-C-C-C-C—C-C-C (VIII) cr Serotonin (5HT3) receptor
aS Nicotinic receptors
P (35) C-C-C-C-C-C (IX) None defined Unknown
lL/l2 (36) C-C-CC-CC-C-C (XI) None defined I<+ channels







2 Adapted from Ref. 4; the individual conopeptide families and their targets are described in that review, which cites the primary literature. 
This Cys pattern was referred to as Framework X or as Framework 1 by different groups (22,38).
changes suggest special mutational/recombination mecha­
nisms targeting mature toxin regions preferentially (involve­
ment of a mutagenic DNA polymerase has been specifically 
suggested) (13, 14). Notable genetic events that generated 
major groups of peptides in the A-superfamily have been 
described (14). In contrast to the mature peptide regions, other 
elements in Conus peptide genes are much more conserved 
(including some intronic regions). Signal sequences, usually the 
least conserved element of a secreted polypeptide, are so 
extremely conserved that unusual genetic events (such as gene 
conversion) seem likely to play a role in maintaining signal 
sequence conservation.
Peptides of the same superfamily generally share a character­
istic arrangement of Cys residues in the mature toxin region 
(the “Cys pattern”); each Cys pattern usually corresponds to a 
specific disulfide framework. However, in two gene superfami­
lies, each with a conserved Cys pattern, the disulfide connectiv­
ity changed as spacing of amino acids between Cys residues 
changed (15,16). Thus, although peptides in a gene superfamily 
usually have similar structures, groups of peptides with new 
disulfide scaffolds can occasionally evolve within a superfamily. 
How small peptides with multiple Cys residues are folded such 
that only one disulfide framework is formed in vivo is a funda­
mental issue not yet satisfactorily addressed; if oxidative folding 
is carried out in vitro, multiple disulfide isomers are generated; 
the peptide with the native scaffold must be purified from other 
folding isomers. Preliminary indications suggest that the “Pro” 
region of Conus peptide precursors contributes at least indi­
rectly to facilitate correct folding (17,18).
Rapid Gene Superfamily Sequence Divergence Leads to 
Functional Diversification
Conus peptide superfamilies have functionally differentiated; 
consequently, different peptides in the same superfamily may 
have different classes of physiological targets. Some examples 
are shown in Table 2; the M-superfamily includes the 
/n-conopeptide family (N af channel blockers), the 
xM-eonopeptide family (I<+ channel blockers), and the 
(/(-conopeptide family (non-competitive nicotinic receptor 
antagonists). These groups of peptides are genetically and 
structurally related with similar Cys patterns, disulfide scaf­
folds, and three-dimensional structures, but they have func­
tionally diverged. In contrast, ligand sites of peptides in the 
same family  are expected to be homologous {i.e. /n-eonopeptide 
binding sites on various N a 1 channel subtypes).
However, within a single Conus peptide family, individual 
peptides may differ in targeting selectivity. a-Conopeptides are 
nicotinic receptor antagonists, but different a-eonopeptides 
may target different receptor subtypes. Thus, a Conus peptide 
family can provide a ligand panel selective for different molec­
ular isoforms of a general target class. An important corollary is 
that it is possible to change targeting specificity of Conus pep­
tides by appropriate amino acid substitutions (for a specific 
example, see Ref. 19).
Peptides that belong to different families may play analogous 
functional roles in different lineages of Conus species. Three 
different peptide families targeted to the KV1 subfamily of volt­
age-gated I<+ channels, the K-eonotoxins, the eonkunitzins

























FIGURE 1. Incorporating phylogeny into biochemical discovery. The figure shows a panel of n-conopeptides targeted to different nicotinic receptor 
subtypes (top), the prepropeptide precursor sequences of some of these n-conopeptides (middle panel), and the Conus species these were derived from 
(bottom panel). Top, a venom peptide targeting muscle nicotinic receptors, n-MI, a member of the n-conopeptide family, was purified from C. magus venom 
(Phase 1). cDNA libraries from species in Pionoconus, in the same subgenus as C. magus (C. monachus, C. consors, C. stercusmuscarum, C. striatus), yielded other 
family members (Mn1.6,Cn1.1,Sm 1.1, and SIA) with the same muscle subtype selectivity (shown as superscript 1) as n-MI; in the C. magus cDNA library, a second 
family member, n-MII, was identified with different subtype selectivity (neuronal n302, shown as superscript 2) (Phase 2A). Analysis of species less closely 
related to C. magus and not in Pionoconus (C.regius,C.brunneus,C. imperialis, C. purpurascens, C. aulicus) uncovered n-family members that were more divergent 
(Phase 2B). Although these peptides also target nicotinic receptors, they have different subtype selectivity (AulB:n304 (superscript 3), PIA:n602 (superscript 4), 
RglA:n9n10(supersoipf5), Iml, n7-l n302 (superscript 6), nlmll,n7 (superscript 7)). M iddle panel, complete amino acid sequences of some n-conopeptide family 
precursors are shown; mature peptide sequences are at the C terminus after the arrow, the site of proteolytic cleavage releasing the mature peptide toxin. The 
conserved N-terminal region as well as the pattern of Cys residues in the mature peptide (both boxed) clearly identifies these peptides as members of the 
A-conopeptide superfamily. All members of the superfamily targeted to the nicotinic receptor family and exhibiting the characteristic Cys pattern (CC—C—C) 
belong to the n family. Note that the first two sequences encode peptides that belong to the n3/5 subfamily, whereas the bottom three are members of two 
other subfamilies. Bottom panel, phylogenetic tree. The relationship of C. magus to other species is shown in the phylogenetic tree based on 16 S sequences. 
The red branches show species in the subgenus Pionoconus, and the purple branch is a fish hunter in Chelyconus.the green branch shows a mollusk hunter (C. 
aulicus). The uncolored branches are worm-hunting species that specialize in amphinomid polychaetes; these express n-conopeptides in the n4/3 subfamily.

























(14), and the kM conotoxins (18), are completely unrelated 
genetically and structurally. Three different clades of fish-hunt­
ing cone snails each evolved peptides belonging to the three 
unrelated gene families for parallel physiological purposes 
(blocking the KV1 subfamily of K f channels, as part of the “exci- 
totoxic shock” strategy to rapidly immobilize fish prey) (20, 21). 
Although different clades of Conus species utilize different 
conopeptide families to inhibit the KV1 subfamily of K f chan­
nels, all of these clades use the same family, the S-conopeptides, 
to inhibit Na f channel inactivation (20). Thus some conopep­
tide families are found in a single clade comprising a few spe­
cies, whereas others appear to be found in all —700 Conus 
species.
Systematic Discovery and Characterization of Conus 
Peptides Using Phylogenetics
In recent years, Conus peptide discovery has become more 
efficient by integrating phylogenetics into the discovery strat­
egy. A prime example of systematic discovery using such a phy- 
logenetically informed strategy has been the a-conopepide 
family peptides, which target nicotinic receptors. Some Conus 
species from which a-conotoxins have been characterized are 
shown in Fig. 1; major a-conopeptides from different species 
are shown. The first group analyzed were fish-hunting Conus 
belonging to one clade, the subgenus Pionoconus; the major 
a-conopeptides found belong to the same subfamily of 
a-conopeptides (the a3/5 subfamily) that specifically target the 
muscle nicotinic receptor subtype. Scanning different 
sequences of a3/5 subfamily peptides provides structure-func- 
tion information; the pattern of amino acid conservation iden­
tifies the likely functionally important residues.
By analyzing species less related to C. magus (in clades other 
than Pionoconus), other a-conopeptide subfamilies were identi­
fied. The worm-hunting species Conus imperialis, regius, and 
brunneus express peptides in the a4/3 subfamily, primarily tar­
geted to homomeric nicotinic receptor subtypes (Le. a7, a9, alO) 
(22-24) instead of to the muscle subtype. Thus, a systematic sweep 
of biodiversity can be used to identify groups of peptides in the 
same family, which have diverged in target selectivity. Closely 
related species yield functionally homologous peptides; more 
divergent species express family members likely to have different 
(but related) molecular targets. This discovery strategy has pro­
vided the neuroscience community with a panel of a-conopep­
tides diagnostic for various nicotinic receptor subtypes.
Perspectives
Every Conus species has a repertoire of 100 -200 conopep­
tides with essentially no overlap between different species. The 
venom peptide families rapidly diversify. The conopeptide rep­
ertoire of a particular cone snail species mediates interactions 
between that species and its prey, predators, and competitors 
(2). Thus venom peptide genes are sculpted by natural selection 
to the ecological singularities of the individual species.
In any megadiverse group of related animals such as the cone 
snails, most of the genome would be expected to be largely con­
served if the different species within the group were compared. In 
contrast, genes responsible for mediating interactions with other 
animals in the environment, such as the conopeptide genes, have
to diversify rapidly because each species has its own ecological 
niche. The spectrum of biotic interactions of a species differs from 
that of all others; this is the perspective that rationalizes why a 
distinctive complement of venom peptides is found in each of the 
—700 different Conus species. Thus, the evolutionary history of 
such genes would be expected to be strikingly different from most 
of the rest of the genome, a hypothesis strongly supported by the 
accumulating data on Conus peptide genes.
The rapidly diversifying genes encoding Conus peptides are, 
we believe, not at all unique in their evolutionary behavior; they 
are merely the first major class of such genes to have been 
extensively characterized from a substantial number of related 
animal species. The rationale above for why venom peptide 
genes rapidly diversify leads to the expectation that in general, 
genes whose products act on other animals in the environment 
will evolve extremely rapidly. For other megadiverse animal 
lineages, similarly rapidly diversifying genes should be a major 
genetic foundation for generating biodiversity.
The molecular genetic revolution has been based on a few 
model organisms (Escherichia coli, yeast, Caenorhabditis 
elegans, Drosophila, zebra fish, and mice), and these models 
provide a powerful common framework for understanding 
genes that encode central physiological functions. Conus pep­
tide genes are qualitatively different; their gene products are 
exogenously targeted. Although the endogenous physiology of 
different species in Conus is likely to be closely similar, exoge­
nous interactions with prey, predators, and competitors differ 
sharply between species. The genes whose ultimate gene prod­
ucts act on the physiology of a different organism will thus be 
expected to comprise a part of the genome greatly accelerated 
in its rate of evolution. It is useful to distinguish this rapidly 
diversifying sector of the genome from the general class of 
“endogenously targeted” genes by the term “exogenome.”
To understand biodiversity, particular attention needs to be 
paid to the exogenome; understanding how evolution of the 
exogenome is accelerated may hold the key to understanding 
speciation at a molecular level. The work on Conus peptide 
genes has revealed some esoteric and remarkable features 
including an unprecedented rate of the divergence of mature 
peptide regions juxtaposed with an almost total conservation of 
signal sequences. W ill these features also be characteristic of 
genes in the exogenomes of other megadiverse taxa? The 
unusual features of conopeptide genes may well be generally 
diagnostic of the exogenome, consisting of genes that diversify 
rapidly as speciation occurs. Identifying genes comprising the 
exogenome, determining whether these systematically differ in 
their organization from other genes, and learning how to rap­
idly deduce and express or synthesize the gene products that 
they encode should coalesce into an organized genomic subdis­
cipline, exogenomics, that has enormous potential for future 
biomedical/pharmacological discovery.
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